Regarding the specific subpopulation of pregnant women not fulfilling the APS criteria, and especially aPL carriers, LDA is usually part of the therapeutic strategy (19), even if the available studies failed to demonstrate its efficacy (20, 21). This evidence concerns the gene FASLG and autoimmune polyendocrinopathy.